AnaptysBio, Inc. - Common Stock (NQ:ANAB)

48.53 -0.10 (-0.21%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Key Takeaways From AnaptysBio Analyst Ratings ↗

December 02, 2024

Via Benzinga

Anaptys Announces Participation in November and December Investor Conferences

November 05, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

November 05, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 30, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts ↗

October 21, 2024

Via Benzinga

What Analysts Are Saying About AnaptysBio Stock ↗

September 26, 2024

Via Benzinga

Insiders Buying Yum China And 2 Other Stocks ↗

August 19, 2024

Via Benzinga

4 Analysts Assess AnaptysBio: What You Need To Know ↗

August 06, 2024

Via Benzinga

O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 30, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 30, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 30, 2024

Via Benzinga

Anaptys Announces Participation in September Investor Conferences

August 29, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

The Analyst Landscape: 7 Takes On AnaptysBio ↗

May 10, 2024

Via Benzinga

Unveiling 4 Analyst Insights On AnaptysBio ↗

April 01, 2024

Via Benzinga

Why AnaptysBio Was Such a Healthy Stock This Week ↗

August 23, 2024

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

Via The Motley Fool

UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday ↗

August 14, 2024

Via Benzinga

AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering ↗

August 14, 2024

The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.

Via Investor's Business Daily

S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday ↗

August 14, 2024

US inflation eases in July, keeping Fed rate cut hopes alive. Stocks rise, yields stable, dollar gains against yen. Tech and small caps outperform.

Via Benzinga

Topics ETFs Economy Stocks

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

August 14, 2024

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi

From AnaptysBio, Inc.

Via GlobeNewswire

ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 ↗

August 05, 2024

ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

August 05, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst ↗

July 22, 2024

HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.

Via Benzinga

ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 09, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

May 09, 2024

From AnaptysBio, Inc.

Via GlobeNewswire

BTIG Research Predicts Over 118% Rally for These 3 Stocks ↗

April 15, 2024

Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.

Via InvestorPlace

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week ↗

April 12, 2024

A powerfully bullish new analyst take on the company helped it rally on the market.

Via The Motley Fool

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 11, 2024

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Via Benzinga

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 11, 2024

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.